ArticleInternational journal of women's health2026
Integrative Multi-Omics Analysis Unveils Biomarkers Linking the Gut Microbiota, Blood Metabolites, and Recurrent Pregnancy Loss.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Emerging evidence suggests that dysbiosis of gut microbiota and metabolic disturbance can adversely affect reproductive health. This study seeks to shed light on the connection between gut microbiota, blood metabolites, and recurrent pregnancy loss (RPL), and identify potential biomarkers linking them. Patients and Methods: The associations of gut microbiota and blood metabolites with RPL were explored through Mendelian randomization (MR) and mediation analyses. Differential expression analysis combined with three machine learning algorithms was then used to identify biomarkers that link the gut microbiota-blood metabolite network in RPL. Additionally, a nomogram was constructed to evaluate their predictive performance for RPL. On this basis, immune infiltration analysis and single-cell RNA sequencing (scRNA-seq) were further conducted to gauge the immune characteristics of RPL. Results: A total of 28 gut microbiota and 82 blood metabolites/metabolite ratios showed significant potential associations with RPL. Among them, mediation analysis revealed that 3-amino-2-piperidone amplified the hazardous effect of Conclusion: Significant potential links were observed between the gut microbiota, blood metabolites, and RPL. Integrative multi-omics analysis further identified key biomarkers linking gut microbiota, blood metabolites, and RPL, and highlighted the role of the gut microbiota-metabolites-immune axis in the pathogenesis of RPL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.